MedTrace Logo

A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain

NCT02192190 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 268

Last updated 2019-09-10

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to test if LY2951742 relieves mild to moderate knee pain. The study drugs will be given as an injection under the skin and as an oral capsule. The study will last about 28 weeks for each participant.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

LY2951742

Administered subcutaneously (SC)

OTHER

Placebo- oral

Administered orally

OTHER

Placebo - SC

Administered SC

DRUG

Celecoxib

Administered orally

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-04-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02192190 on ClinicalTrials.gov